Solid Tumor — Expanded Access Programs
Overview
Right2Hope maintains a directory of 68 expanded access programs, clinical trials, and compassionate use pathways listed for Solid Tumor. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with solid tumor programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 18 programs are currently active or recruiting, with the remaining 50 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, Mirati Therapeutics Inc., ImmVira Pharma Co. Ltd, Merck Sharp & Dohme LLC, Monopar Therapeutics, and others.
By recruiting status
Snapshot of where every Solid Tumor program currently sits in its lifecycle.
- Active / Recruiting18
- Draft1
- Inactive49
Top sponsors
Organisations running the most Solid Tumor programs in the directory.
- Memorial Sloan Kettering Cancer Center4 programs
- Mirati Therapeutics Inc.3 programs
- ImmVira Pharma Co. Ltd2 programs
- Merck Sharp & Dohme LLC2 programs
- Monopar Therapeutics2 programs
- Novartis Pharmaceuticals2 programs
- 23andMe, Inc.1 program
- A2 Biotherapeutics Inc.1 program
- Affini-T Therapeutics, Inc.1 program
- Alyssum Therapeutics1 program
Solid Tumor programs (68)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on the Safety and Effectiveness of GSK4418959 Alone or with Other Cancer Drugs in Patients with Solid Tumors — GlaxoSmithKline
- Study on ENB003 and Pembrolizumab for Treating Solid Tumors — ENB Therapeutics, Inc
- Extended Access to Ibrutinib for Patients Benefiting from Treatment — Pharmacyclics Switzerland GmbH
- First-in-Human Study of CRB-601-01 for Treating Advanced Solid Tumors — Corbus Pharmaceuticals Inc.
- Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
- Study on Givastomig with Nivolumab and Chemotherapy for Adults with CLDN18.2 Positive Metastatic Stomach Cancer — I-Mab Biopharma US Limited
- Expanded Access Program for MNPR-101-DFO*-89Zr in Patients with Solid Tumor Cancer — Monopar Therapeutics
- Expanded Access Program for MNPR-101-PCTA-177Lu in Patients with Solid Tumor Cancer — Monopar Therapeutics
- Phase 1/2 Study of S241656 for Cancers with Specific RAS/MAPK Mutations — Institut de Recherches Internationales Servier
- Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
- Study on the Safety and Dosage of Neratinib for Children and Young Adults with Cancer That Has Returned or Not Responded to Treatment — Memorial Sloan Kettering Cancer Center
- Study on the Safety and Early Effects of SA53-OS in Patients with Advanced or Metastatic Solid Tumors — Lamassu Bio Inc
- Study on the Safety and Tolerability of TNG456 Alone and with Abemaciclib in Patients with Solid Tumors with MTAP Loss — Tango Therapeutics, Inc.
- Study on STC-15 and Toripalimab Combination Therapy for Advanced Cancers — STORM Therapeutics LTD
- Study of Tilsotolimod with Nivolumab and Ipilimumab for Treating Solid Tumors (ILLUMINATE-206) — Idera Pharmaceuticals, Inc.
- Study on IMP9064 as a Standalone or Combined Treatment for Advanced Solid Tumors — Impact Therapeutics, Inc.
- Extension Study for Patients Previously in Pelabresib Trials — Constellation Pharmaceuticals
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on Intratumoral T3011 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — ImmVira Pharma Co. Ltd
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on SAR445877 for Adults with Advanced Solid Tumors — Sanofi
- Study on PBI-410 for Advanced Solid Tumors — Biohaven Therapeutics Ltd.
- Study on MRTX0902 for Treating Solid Tumors with KRAS MAPK Pathway Mutations — Mirati Therapeutics Inc.
- Study on OTX-2002 for Liver Cancer and Other Tumors Linked to the MYC Gene — Omega Therapeutics
- Phase 1/2 Study on the Safety and Effectiveness of YH42946 for Advanced Solid Tumors with HER2 and EGFR Mutations — Yuhan Corporation
- Phase 2 Study of Avutometinib (VS-6766) and Defactinib for Gynecological Cancers — University of Oklahoma
- Study on the Safety and Effectiveness of HLA-G-Targeted CAR-T Cells IVS-3001 in Patients with Previously Treated Advanced HLA-G-Positive Solid Tumors — M.D. Anderson Cancer Center
- Study on 177Lu-FAP-2286 for Advanced Solid Tumors — Novartis Pharmaceuticals
- Study on NDI 1150-101 for Patients with Advanced Solid Tumors — Nimbus Saturn, Inc.
- Study of Pembrolizumab in Children with Advanced Solid Tumors or Lymphoma — Merck Sharp & Dohme LLC
- Study on REC-4881 for Treating Cancers with AXIN1 or APC Mutations — Recursion Pharmaceuticals Inc.
- Study on RP-3500 with Radiation Therapy for People with Solid Tumor Cancer — Memorial Sloan Kettering Cancer Center
- Study on Selinexor for Treating Wilms Tumors and Other Solid Tumors — Memorial Sloan Kettering Cancer Center
- Study on IPN01194 for Adults with Advanced Solid Tumors — Ipsen
- Study on the Safety and Effectiveness of PRL3-Zumab for Patients with Solid Tumors — Intra-IMMUSG Pte Ltd
- A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors — Eutilex
- Study on the Effectiveness and Safety of TL118 for Patients with Solid Tumors — Teligene US
- Study on the Safety, Tolerability, and Effectiveness of Farletuzumab Ecteribulin for Certain Cancer Types — Eisai Inc.
- ALG.APV-527 First-in-human Study — Aptevo Therapeutics
- Study for Continued Access to Dabrafenib and/or Trametinib Treatment — Novartis Pharmaceuticals
- First-in-Human Trial of VERT-002 for Patients with Advanced Solid Tumors with MET Changes — Pierre Fabre Medicament
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- JAB-3312 Combination Therapy for Adults with Advanced Solid Tumors — Jacobio Pharmaceuticals Co., Ltd.
- Study on LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab for Advanced or Metastatic Solid Tumors — PureTech
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — Incyclix Bio
- Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Select Solid Tumors — Vyriad, Inc.
- Phase 1/2 Study of MRTX1719 for Solid Tumors with MTAP Gene Deletion — Mirati Therapeutics Inc.
- Phase I Study of Personalized T Cell Therapy for Advanced or Metastatic Solid Tumors with KRAS G12V Mutation — Affini-T Therapeutics, Inc.
- Phase II Study of Tazemetostat for Solid Tumors with ARID1A Mutation — Prisma Health-Upstate
- Study on RAPA-201 Therapy for Solid Tumors — Rapa Therapeutics LLC
- Study on the Safety and Early Effects of TYRA-300 in Advanced Bladder Cancer and Other Tumors with FGFR3 Gene Changes — Tyra Biosciences, Inc
- Safety and Early Effectiveness Study of BNT142 in Patients with CLDN6-positive Solid Tumors — BioNTech SE
- Study on the Safety and Tolerability of GIM-531 for Advanced Solid Tumors — Georgiamune Inc
- Study on SB-4826 for Adults with Advanced Solid Tumors or Non-Hodgkin Lymphomas — University of California, San Diego
- Study on Sirolimus and Metronomic Chemotherapy for Children with High-Risk Solid Tumors — Emory University
- Study on SKB264 and Pembrolizumab for Treating Certain Solid Tumors — Klus Pharma Inc.
- Study on SMP-3124LP for Adults with Advanced Solid Tumors — Sumitomo Pharma America, Inc.
- Study on 23ME-01473 for Patients with Advanced Solid Cancers — 23andMe, Inc.
- Study on Favezelimab and Pembrolizumab for Treating Certain Solid Tumors — Merck Sharp & Dohme LLC
- Study on INBRX-106 Alone and with Pembrolizumab (Keytruda®) for Advanced Solid Tumors — Inhibrx Biosciences, Inc
- Study on Using PD-1 Blockade for Treating Locally Advanced Mismatch Repair Deficient Solid Tumors — Memorial Sloan Kettering Cancer Center
- Study on MRTX1133 for Patients with Advanced Solid Tumors with a KRAS G12D Mutation — Mirati Therapeutics Inc.
- Study on TU2218 and Pembrolizumab Combination for Advanced Solid Tumors — TiumBio Co., Ltd.
- Study on the Safety and Effects of AT-1965 in Patients with Advanced Solid Tumors — Alyssum Therapeutics
- Study on Tovorafenib (DAY101) Alone or with Other Treatments for Melanoma and Other Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on Atezolizumab with Chemotherapy for Children with Relapsed or Hard-to-Treat Solid Tumors — University of Texas Southwestern Medical Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Solid Tumor to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.